These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 21470623

  • 1. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
    Krukemeyer MG, Krenn V, Jakobs M, Wagner W.
    J Surg Res; 2012 Jun 01; 175(1):35-43. PubMed ID: 21470623
    [Abstract] [Full Text] [Related]

  • 2. Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets - sarcoma treatment in progress.
    Krukemeyer MG, Krenn V, Jakobs M, Wagner W.
    J Drug Target; 2012 Feb 01; 20(2):185-93. PubMed ID: 22044194
    [Abstract] [Full Text] [Related]

  • 3. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
    Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F.
    J Drug Target; 2003 Apr 01; 11(3):139-49. PubMed ID: 13129824
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacokinetics, tissue distribution and magnetic resonance's response characterstics of folic acid-O-carboxymethyl chitosan ultrasmall superparamagnetic iron oxide nanoparticles in mice and rats].
    Gao WH, Liu ST, Fan CX, Qi LY, Chen ZL.
    Yao Xue Xue Bao; 2011 Jul 01; 46(7):845-51. PubMed ID: 22010356
    [Abstract] [Full Text] [Related]

  • 5. Locoregional cancer treatment with magnetic drug targeting.
    Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lübbe AS.
    Cancer Res; 2000 Dec 01; 60(23):6641-8. PubMed ID: 11118047
    [Abstract] [Full Text] [Related]

  • 6. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice.
    Reszka R, Beck P, Fichtner I, Hentschel M, Richter J, Kreuter J.
    J Pharmacol Exp Ther; 1997 Jan 01; 280(1):232-7. PubMed ID: 8996201
    [Abstract] [Full Text] [Related]

  • 7. Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles.
    Dürr S, Lyer S, Mann J, Janko C, Tietze R, Schreiber E, Herrmann M, Alexiou C.
    Anticancer Res; 2012 May 01; 32(5):1983-9. PubMed ID: 22593476
    [Abstract] [Full Text] [Related]

  • 8. Studies on the adsorption and desorption of mitoxantrone to lauric acid/albumin coated iron oxide nanoparticles.
    Zaloga J, Feoktystov A, Garamus VM, Karawacka W, Ioffe A, Brückel T, Tietze R, Alexiou C, Lyer S.
    Colloids Surf B Biointerfaces; 2018 Jan 01; 161():18-26. PubMed ID: 29035747
    [Abstract] [Full Text] [Related]

  • 9. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
    Lu B, Xiong SB, Yang H, Yin XD, Chao RB.
    Eur J Pharm Sci; 2006 May 01; 28(1-2):86-95. PubMed ID: 16472996
    [Abstract] [Full Text] [Related]

  • 10. Biodistribution and targeting properties of iron oxide nanoparticles for treatments of cancer and iron anemia disease.
    Alphandéry E.
    Nanotoxicology; 2019 Jun 01; 13(5):573-596. PubMed ID: 30938215
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC, Pei J, Zhang C, Ahmad I, Rahman A, Kasid U.
    Anticancer Res; 2001 Jun 01; 21(5):3313-21. PubMed ID: 11848489
    [Abstract] [Full Text] [Related]

  • 15. Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide nanoparticles in rats and the potential health risk assessment.
    Zhu MT, Feng WY, Wang Y, Wang B, Wang M, Ouyang H, Zhao YL, Chai ZF.
    Toxicol Sci; 2009 Feb 01; 107(2):342-51. PubMed ID: 19023088
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
    Elford P, Bouchard J, Jaillet L, Pearson N, Rogue A, Sabadie C, Forster R.
    J Pharmacol Toxicol Methods; 2013 Feb 01; 68(3):374-83. PubMed ID: 23624021
    [Abstract] [Full Text] [Related]

  • 18. Effect of magnet implant on iron biodistribution of Fe@C nanoparticles in the mouse.
    Escribano E, Fernández-Pacheco R, Valdivia JG, Ibarra MR, Marquina C, Queralt J.
    Arch Pharm Res; 2012 Jan 01; 35(1):93-100. PubMed ID: 22297747
    [Abstract] [Full Text] [Related]

  • 19. [Biodistribution of N-(2-hydroxypropyl) methacrylamide copolymer-bound mitoxantrone in mice bearing Ehrlich solid tumor].
    Huang Y, Zhang Z, Liu W.
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Dec 01; 21(6):930-4. PubMed ID: 15646335
    [Abstract] [Full Text] [Related]

  • 20. [Studies on lung targeting gelatin microspheres of mitoxantrone].
    Wang JH, Lu B, Xu PL, Bao DY, Zhang ZR.
    Yao Xue Xue Bao; 1995 Dec 01; 30(7):549-55. PubMed ID: 7484159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.